Our population-based study suggests that long-term survivors of HL treated with RT before 35 years of age have a significantly higher risk of developing ER-negative/PR-negative than ER-positive/PR-positive BC, particularly among 15-year survivors. This evidence concerns the gene PGR and breast cancer.